The new company President, Kenneth P. Glynn is an attorney by background, specializing in patents: Glynn & Associates PC (908) 788-0077 24 Mine St Flemington, NJ 08822 http://www.usipattorneys.com/MemberDetails.aspx?MemberID=19323 In the 8k form, the company stated that it would persue a line of solar products (batteries, etc.)
Put the pieces of this puzzle together and it may spell anything along the lines of 'merger' or maybe more...
Could it be that the very same individual involved with patents has discovered a new and revolutionary idea that will improve existing solar battery technology? But what goals would such an individual have in mind? Most likely the intention of bringing this idea to the public market in order to 'market' the innovation to a 'big' solar industry player interested in aquiring the technology (and naturally, the company itself). This is why Mr. Glynn "established the Kenergy Scientific Group to seek new products to be sold under the Kenergy Scientific brand".
What are we looking at if news of an SSWC reverse merger hits the wires? Just look at its IVOI brethren, each rallied well over 1,000%. That would put SSWC at $.004 or better, that's from today's closing price of $.0004 a share.
IP: Logged |
SpeechSwitch, Inc. (USOTC: SSWC) Filing Health Care Patent Applications for Advanced Biodegradable Wound Care Products SpeechSwitch,. Class A (OTC) (USOTC:SSWC) Intraday Stock Chart Today : Monday 28 June 2010
Ken Glynn, President of SpeechSwitch, Inc. (PINKSHEETS: SSWC), announced today that the Health Care Division is developing three new inventions and filing three patent applications relating to wound care. One of the inventions involves biodegradable, disposable band-aids and bandages utilizing biodegradable support strips and adhesives with natural algae biomimetic artificial skin material that accelerates healing and absorbs naturally into the body. A second invention utilizing the same wound care technology involves other treatment enhancements included within the biomimetic artificial skin material. The third invention is a collaboration between Dr. Alain Martin and Ken Glynn, as co inventors, utilizing the same wound care technology, but including Dr. Martin's proprietary antioxidant, anti-inflammatory cell growth accelerants. Dr. Martin is the inventor of Neosporin and other successful products, and is currently the CEO of North Cell Pharmaceutical, Inc. SpeechSwitch and North Cell will be equal partners in this alliance.
In other news, Ken announced that he will be interviewed today by the Wall Street Reporter and that the interview will be posted later this week.
Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
